fenofibrate/pravastatin / Generic mfg. - LARVOL DELTA

Safety and Immunogenicity Study of the DuoChol Oral Cholera Vaccine in Healthy Participants (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: International Vaccine Institute

New P1 trial • Cholera

Uptake likelihood assessment of oral cholera vaccine capsules: insights from stakeholder consultations in five countries. (PubMed, BMC Public Health) - "The stakeholders highlighted that vaccine capsules are desirable for use in the general population as they have the potential to have many advantages over the current practice. However, for children who are not able to swallow the capsule, the currently available liquid oral cholera vaccine may be more desirable. To make an eventual informed decision about whether to recommend use of the vaccine capsule, national stakeholders requested the generation of evidence derived from pilot studies."

Journal • Cholera

DuoChol- an encapsulated thermostable oral cholera vaccine (OCV) - Development plan and User Acceptance Evaluation (ASTMH 2024) - No abstract available

Cholera

94 - Solving the Supply Shortage: Present and Future Prospects for Cholera Vaccines (ASTMH 2024) - "Additional presentations will include the Phase 1 trial results of PanChol a genetically engineered rapid-acting live attenuated Oral Cholera Vaccine, and the Phase 1 trial results of a Cholera Conjugate Vaccine (CCV) based on the immunodominant protective antigen of cholera, the O-specific polysaccharide (OSP) component of LPS, linked to a carrier protein to generate T cell dependent responses...Finally, the development plan of a novel oral capsule vaccine, DuoChol, that combines inactivated whole cell bacteria and recombinant cholera toxin B will be presented including the results of country workshops in South Asia and Sub-Saharan Africa to assess feasibility, cost and policy implications of a capsule vaccine. This highly thermostable and light weight vaccine is expected to have efficacy similar to Dukoral but significantly reduce delivery costs and challenges. A phase 1 trial is expected in early 2025."

Cholera

Efficacy and safety study of sorafenib plus pravastatin to treat advanced hepatocarcinoma (ESTAHEP-2010) (clinicaltrials.gov) - P2, N=216; ESTAHEP-2010; Not yet recruiting -> Recruiting

Enrollment open • Hepatocellular Cancer • Oncology

Efficacy and safety study of sorafenib plus pravastatin to treat advanced hepatocarcinoma (ESTAHEP-2010) (clinicaltrials.gov) - P2, N=216; Not yet recruiting; New P2 trial

New trial • Hepatocellular Cancer • None • Oncology